抗抑郁治疗对COPD合并抑郁症疗效的临床观察

The Observation of Influence of Anti-depression Therapy in the Treatment of COPD Combined with Depressive Disorder

目的分析抗抑郁治疗对慢性阻塞性肺疾病(COPD)合并抑郁症患者的治疗价值。方法选取2011年1月至2013年3月邯郸市第一医院收治的COPD合并抑郁患者72例,依据随机数字表法分为两组:联合用药组(36例)采用沙丁胺醇联合帕罗西汀治疗,帕罗西汀组(36例)单纯使用帕罗西汀治疗,比较两组治疗后3个月的汉密尔顿抑郁量表(HAMD)评分、血气指标、2年内呼吸衰竭发生率和进展至呼吸衰竭的时间。结果治疗后联合用药组HAMD评分显著低于帕罗西汀组(P<0.05);治疗后联合用药组的氧分压显著高于帕罗西汀组,二氧化碳分压显著低于帕罗西汀组患者(P<0.05);联合用药组的呼吸衰竭发生率显著低于帕罗西汀组,进展至呼吸衰竭的时间显著长于帕罗西汀组(P<0.05)。结论抗抑郁治疗能够显著改善COPD患者的预后,延缓呼吸衰竭的发生时间。

Objective To analyze the influence of anti-depression therapy in the treatment of COPD combined with depressive disorder. Methods From January 2011 to March 2013,72 COPD combined with depressive disorder patients admitted to Handan City First Hospital were divided into two groups based on a random number table ： observation group （ 36 cases） using salbutamol parexetine treatment, control group （ 36 cases） using only paroxetine. HAMD scores, blood gas, incidence of respira- tory failure in 2 years and the development time of respiratory failure of the two groups were compared. Results HAMD of the observation group was lower than the control group （ P 〈 0.05 ） ; PaO2 of the observation group was higher than the control group, and the PaCO2 was lower than the control group （P 〈 0.05 ）. Incidence of respiratory failure in the observation group was lower than the control group, and the development time of respiratory failure was longer than the control group（ P 〈 O. 05 ）. Conclusion Anti-depression therapy can significantly improve the prognosis of COPD and delay the development into respiratory failure.